PCT for Speech, Language, and Cognitive Intervention in Stroke Patients
Aphasia, Acquired
About this trial
This is an interventional treatment trial for Aphasia, Acquired
Eligibility Criteria
Inclusion criteria:
- Have diagnosis of stroke involving a hemorrhage or ischemic event, resulting in speech, language, and/or cognitive deficits
- Have time post-stroke of at least 4 months prior to enrollment
- Have been discharged from rehabilitation hospital
- Are adults (aged 18 years or older) at the time of consent
- Exhibit clinically confirmed speech, language, and/or cognitive deficits based on medical records
- Are fluent English speakers
- Have confirmed aphasia using the WAB-R Aphasia Quotient (score of 90 or lower; 93.8 is cutoff for normal scores)
- Have a presence of a family member or caregiver who is willing and able to provide assistance during the duration of study period
Exclusion Criteria:
- Have comorbid neurological conditions that could impair study participation in the opinion of the investigator, such as dementia or Parkinson's disease
- Currently require inpatient care or acute care
- Are currently undergoing related one-on-one individual therapy at a hospital, rehabilitation facility, university, or at home
- Exhibit severe apraxia of speech or severe dysarthria of speech, as verified by a clinician and confirmed by the WAB-R (and the Screen for Dysarthria and Apraxia of Speech if necessary), and/or medical records
- Have comorbid psychiatric conditions that could impair study participation in the opinion of the investigator, including such as schizophrenia or major depressive disorder, as indicated by medical records
- Have uncorrected hearing or vision loss
Sites / Locations
- The Learning Corp
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Experimental Group
Control Group 1 [Conventional Workbook Therapy]
At the start of the study, subjects will be provided with a tablet with videoconferencing software and the PCT app pre-installed. Research staff will remotely setup a PCT account for the subjects, and provide instructions for logging into the PCT application. During the treatment period, patients will be instructed to use PCT for at least 30 minutes a day and at least 5 days a week. Performance data (accuracy and latency) will be reported by the PCT software to the treating clinician and will be used to modify task assignment over time. PCT tracks usage of the program so that research staff can access automated reporting of subject use to monitor participant adherence to the treatment program.
At the start of the study, subjects will be provided with a tablet with videoconferencing software and the PCT app pre-installed. Subjects in the control group will be told they will have access to 3-months of PCT after their participation in the study has concluded. Subjects in this group will be provided with a standard regime of paper workbooks and instructions to complete approximately 30 minutes a day at least 5 days a week.